TY - JOUR
T1 - Nanostructures for prevention, diagnosis, and treatment of viral respiratory infections
T2 - from influenza virus to SARS-CoV-2 variants
AU - Sharifi, Esmaeel
AU - Yousefiasl, Satar
AU - Trovato, Maria
AU - Sartorius, Rossella
AU - Esmaeili, Yasaman
AU - Goodarzi, Hamid
AU - Ghomi, Matineh
AU - Bigham, Ashkan
AU - Moghaddam, Farnaz Dabbagh
AU - Heidarifard, Maryam
AU - Pourmotabed, Samiramis
AU - Nazarzadeh Zare, Ehsan
AU - Paiva-Santos, Ana Cláudia
AU - Rabiee, Navid
AU - Wang, Xiangdong
AU - Tay, Franklin R.
N1 - Publisher Copyright:
© 2023, The Author(s).
PY - 2023/12
Y1 - 2023/12
N2 - Viruses are a major cause of mortality and socio-economic downfall despite the plethora of biopharmaceuticals designed for their eradication. Conventional antiviral therapies are often ineffective. Live-attenuated vaccines can pose a safety risk due to the possibility of pathogen reversion, whereas inactivated viral vaccines and subunit vaccines do not generate robust and sustained immune responses. Recent studies have demonstrated the potential of strategies that combine nanotechnology concepts with the diagnosis, prevention, and treatment of viral infectious diseases. The present review provides a comprehensive introduction to the different strains of viruses involved in respiratory diseases and presents an overview of recent advances in the diagnosis and treatment of viral infections based on nanotechnology concepts and applications. Discussions in diagnostic/therapeutic nanotechnology-based approaches will be focused on H1N1 influenza, respiratory syncytial virus, human parainfluenza virus type 3 infections, as well as COVID-19 infections caused by the SARS-CoV-2 virus Delta variant and new emerging Omicron variant. Graphical Abstract: [Figure not available: see fulltext.]
AB - Viruses are a major cause of mortality and socio-economic downfall despite the plethora of biopharmaceuticals designed for their eradication. Conventional antiviral therapies are often ineffective. Live-attenuated vaccines can pose a safety risk due to the possibility of pathogen reversion, whereas inactivated viral vaccines and subunit vaccines do not generate robust and sustained immune responses. Recent studies have demonstrated the potential of strategies that combine nanotechnology concepts with the diagnosis, prevention, and treatment of viral infectious diseases. The present review provides a comprehensive introduction to the different strains of viruses involved in respiratory diseases and presents an overview of recent advances in the diagnosis and treatment of viral infections based on nanotechnology concepts and applications. Discussions in diagnostic/therapeutic nanotechnology-based approaches will be focused on H1N1 influenza, respiratory syncytial virus, human parainfluenza virus type 3 infections, as well as COVID-19 infections caused by the SARS-CoV-2 virus Delta variant and new emerging Omicron variant. Graphical Abstract: [Figure not available: see fulltext.]
KW - Antiviral therapy
KW - Delta variant
KW - Omicron variant
KW - SARS-CoV-2
KW - Viral infections
UR - http://www.scopus.com/inward/record.url?scp=85162714303&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85162714303&partnerID=8YFLogxK
U2 - 10.1186/s12951-023-01938-8
DO - 10.1186/s12951-023-01938-8
M3 - Review article
C2 - 37344894
AN - SCOPUS:85162714303
SN - 1477-3155
VL - 21
JO - Journal of Nanobiotechnology
JF - Journal of Nanobiotechnology
IS - 1
M1 - 199
ER -
